Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The Advanced Merkel Cell Carcinoma pipeline is evolving rapidly to address the unmet needs of this rare and aggressive skin cancer. In the United States, the incidence has stabilized at approximately 0.68 cases per 100,000 person-years, although the total number of cases continues to rise with population aging. Advanced merkel cell carcinoma pipeline analysis by Expert Market Research highlights increasing investment in immune checkpoint inhibitors, targeted therapies, and novel combination strategies aimed at improving long-term patient outcomes.
-
Major companies involved in the Advanced Merkel Cell Carcinoma pipeline analysis include Sensei Biotherapeutics, Inc., Memgen, Inc., and others.
-
Leading drugs currently in the pipeline include BL-M14D1 and others.
-
The pipeline is driven by increasing disease incidence, expanding immunotherapy research, advancements in oncolytic viruses and cell therapies, biomarker-guided treatment strategies, and growing collaborations accelerating innovative therapeutic development.
Report Coverage
The Advanced Merkel Cell Carcinoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into Advanced Merkel Cell Carcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Advanced Merkel Cell Carcinoma. The Advanced Merkel Cell Carcinoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Advanced Merkel Cell Carcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Advanced Merkel Cell Carcinoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Advanced Merkel Cell Carcinoma.
Read more about this report - Request a Free Sample
Advanced Merkel Cell Carcinoma Pipeline Outlook
The Advanced Merkel Cell Carcinoma pipeline continues to gain momentum as immunotherapy innovation and precision oncology reshape treatment strategies for this rare but aggressive skin cancer. A key milestone came in March 2023, when the U.S. FDA granted accelerated approval to Zynyz (retifanlimab-dlwr) for adults with metastatic or recurrent locally advanced Merkel cell carcinoma, expanding first-line treatment options. Advanced Merkel Cell Carcinoma pipeline analysis by Expert Market Research highlights a robust clinical landscape driven by novel immune checkpoint inhibitors, combination therapies, and next-generation immuno-oncology candidates.
Advanced Merkel Cell Carcinoma Epidemiology
Advanced Merkel cell carcinoma is a rare but highly aggressive malignancy, predominantly affecting older adults. A 2026 SEER-based analysis identified 11,574 patients diagnosed between 2000 and 2021, with a median age of 77 years. Since 2013, the incidence has stabilized at approximately 0.68 cases per 100,000 person-years, while mortality has modestly declined following the introduction of immunotherapies. Despite stable incidence, the overall number of cases continues to rise because of population aging, and survival has improved for patients diagnosed in recent years.
Advanced Merkel Cell Carcinoma – Pipeline Therapeutic Assessment
This section of the report covers the analysis of Advanced Merkel Cell Carcinoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The Advanced Merkel Cell Carcinoma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Advanced Merkel Cell Carcinoma Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total Advanced Merkel Cell Carcinoma clinical trials. The pipeline is primarily concentrated in Phase 2 (48.39%), followed by Phase 1 (45.16%), reflecting strong mid-stage clinical development. Phase 3 accounts for 6.45% of candidates, while Early Phase 1 and Phase 4 each represent 0.00%, indicating limited activity at these stages.
Advanced Merkel Cell Carcinoma Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the Advanced Merkel Cell Carcinoma pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The Advanced Merkel Cell Carcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Advanced Merkel Cell Carcinoma. In August 2025, Long-term Phase II POD1UM-201 data showed retifanlimab (Zynyz) achieved a 54.5% objective response rate, with 63% three-year survival, demonstrating durable clinical benefit in advanced Merkel cell carcinoma.
Advanced Merkel Cell Carcinoma Clinical Trials – Key Players
The EMR report for the Advanced Merkel Cell Carcinoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Advanced Merkel Cell Carcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Advanced Merkel Cell Carcinoma clinical trials:
- Replimune, Inc.
- Kupando GmbH
- Sensei Biotherapeutics, Inc.
- Memgen, Inc.
- Marengo Therapeutics, Inc.
- AstraZeneca
- Merck Sharp & Dohme LLC
- SystImmune Inc.
- KaliVir Immunotherapeutics
- TuHURA Biosciences, Inc.
- Incyte Corporation
- Regeneron Pharmaceuticals
Advanced Merkel Cell Carcinoma – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Advanced Merkel Cell Carcinoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Advanced Merkel Cell Carcinoma drug candidates.
Drug: CRD3874
CRD3874 is an investigational small-molecule STING (stimulator of interferon genes) agonist being developed by Replimune, Inc. for advanced solid tumors, including Advanced Merkel Cell Carcinoma. The therapy is designed to activate innate immune signaling within the tumor microenvironment, promoting dendritic cell activation, T-cell priming, and enhanced antitumor immunity. The ongoing Phase I study has an estimated completion in 2029. Replimune is a clinical-stage biotechnology company specializing in innovative immuno-oncology therapies that stimulate systemic and durable anticancer immune responses.
Drug: KUP-101A
KUP-101A is an investigational small-molecule targeted therapy being developed by Kupando GmbH for patients with advanced malignancies, including Advanced Merkel Cell Carcinoma. The candidate is designed to selectively inhibit tumor-promoting molecular pathways while enhancing immune-mediated tumor control, offering a precision medicine approach for difficult-to-treat cancers. The ongoing early clinical program is expected to be completed in 2028. Kupando GmbH is a biotechnology company focused on developing innovative targeted therapies for oncology through translational research and precision drug discovery.
Drug: BL-M14D1
BL-M14D1 is an investigational DLL3-targeted antibody-drug conjugate (ADC) being developed by SystImmune Inc. for neuroendocrine malignancies, including Advanced Merkel Cell Carcinoma. The ADC selectively binds to DLL3-expressing tumor cells and delivers a potent cytotoxic payload, aiming to destroy cancer cells while limiting damage to healthy tissue. The ongoing Phase I study is expected to be completed in December 2027. SystImmune is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-based therapies and ADCs for patients with advanced solid tumors.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Advanced Merkel Cell Carcinoma Pipeline Insight Report
- Which companies/institutions are leading the Advanced Merkel Cell Carcinoma drug development?
- Which company is leading the Advanced Merkel Cell Carcinoma pipeline development activities?
- What is the current Advanced Merkel Cell Carcinoma commercial assessment?
- What are the opportunities and challenges present in the Advanced Merkel Cell Carcinoma pipeline landscape?
- What is the efficacy and safety profile of Advanced Merkel Cell Carcinoma pipeline drugs?
- Which company is conducting major trials for Advanced Merkel Cell Carcinoma drugs?
- Which companies/institutions are involved in Advanced Merkel Cell Carcinoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in Advanced Merkel Cell Carcinoma?
Reasons To Buy This Report
The Advanced Merkel Cell Carcinoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Advanced Merkel Cell Carcinoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Advanced Merkel Cell Carcinoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Transitional Cell Carcinoma Pipeline Analysis Report
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
